Format

Send to

Choose Destination
J Mol Med (Berl). 2003 Apr;81(4):218-26. Epub 2003 Mar 28.

Resistin: molecular history and prognosis.

Author information

1
Division of Endocrinology, Diabetes, and Metabolism, Penn Diabetes Center, University of Pennsylvania School of Medicine, 415 Curie Blvd., Philadelphia, PA 19104-6149, USA.

Abstract

Obesity and diabetes have reached epidemic proportions worldwide. The antidiabetic thiazolidinedione (TZD) drugs are insulin-sensitizing agents now widely used in the treatment of type 2 diabetes. TZDs are ligands for the nuclear hormone receptor peroxisome proliferator activated receptor gamma, which is a master regulator of adipogenesis and adipocyte metabolism. The molecular mechanisms by which TZDs improve insulin sensitivity have not been fully identified. Here we consider a novel secreted factor first identified as a TZD-suppressible gene in mouse adipocytes, called resistin, and discuss what is currently known about resistin regulation and function in mouse and human.

PMID:
12700889
DOI:
10.1007/s00109-003-0428-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center